Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Reata Pharmaceuticals, Inc. (RETA)

49.12   -0.38 (-0.77%) 02-03 15:28
Open: 48.89 Pre. Close: 49.5
High: 50.99 Low: 48.24
Volume: 761,363 Market Cap: 1,800(M)

Technical analysis

as of: 2023-02-03 3:20:12 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 59.55     One year: 69.56
Support: Support1: 40.39    Support2: 33.84
Resistance: Resistance1: 50.99    Resistance2: 59.55
Pivot: 42.13
Moving Average: MA(5): 45.88     MA(20): 40.91
MA(100): 34.51     MA(250): 31.64
MACD: MACD(12,26): 2.6     Signal(9): 1.7
Stochastic oscillator: %K(14,3): 92.6     %D(3): 83.9
RSI: RSI(14): 71.1
52-week: High: 50.99  Low: 18.46
Average Vol(K): 3-Month: 595 (K)  10-Days: 912 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RETA ] has closed below upper band by 2.7%. Bollinger Bands are 56.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 50.06 - 50.25 50.25 - 50.45
Low: 45.33 - 45.55 45.55 - 45.77
Close: 49.13 - 49.48 49.48 - 49.84

Company Description

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Headline News

Fri, 03 Feb 2023
Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside ... - Nasdaq

Fri, 03 Feb 2023
US iriko ikurikirana igipurizo maneko ca China - BBC

Thu, 02 Feb 2023
Reta Chronister Obituary (1944 - 2023) -

Wed, 01 Feb 2023
RETA MARIE MATHIS - Laclede County Record

Wed, 01 Feb 2023
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy ... - Nasdaq

Tue, 31 Jan 2023
Noteworthy Tuesday Option Activity: PYPL, WIX, RETA - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 31 (M)
% Held by Insiders 2.837e+007 (%)
% Held by Institutions 3.3 (%)
Shares Short 4,950 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.5646e+008
EPS Est Next Qtl -0.5
EPS Est This Year -1.76
EPS Est Next Year -2.21
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 576.6
Return on Equity (ttm) -22.9
Qtrly Rev. Growth 1e+007
Gross Profit (p.s.) -60.84
Sales Per Share -147.5
EBITDA (p.s.) -1.33796e+008
Qtrly Earnings Growth -7.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -272 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.34
Price to Cash Flow 4.56

Stock Dividends

Dividend 0
Forward Dividend 5.34e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.